DHEA-S, Androstenedione, 17-β-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: A preliminary investigation
Open Access
- 30 April 2024
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116662
Abstract
No abstract availableKeywords
Funding Information
- Ministero della Salute
This publication has 46 references indexed in Scilit:
- Industry, occupation, and exposure history of mesothelioma patients in the U.S. National Mesothelioma Virtual Bank, 2006–2022Environmental Research, 2023
- Estrogen as a key regulator of energy homeostasis and metabolic healthBiomedicine & Pharmacotherapy, 2022
- Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never‐smoking womenInternational Journal of Cancer, 2022
- Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous analysis of androgens, estrogens, glucocorticoids and progestagens in human serumBiomedical Chromatography, 2022
- Emerging therapies in malignant pleural mesotheliomaCritical Reviews in Oncology/Hematology, 2019
- Measuring estrogens in women, men, and children: Recent advances 2012–2017Clinical Biochemistry, 2018
- Characterization of serum estradiol level and tissue estrogen receptor immunostaining with clinical response and reproductive factor changes in Chinese female patients with esophageal squamous cell carcinomaBiomedicine & Pharmacotherapy, 2017
- Recomendaciones sobre el diagnóstico y manejo de la enfermedad pleural y pulmonar por asbestoArchivos de Bronconeumología, 2017
- Role of postoperative radiotherapy in the management of malignant pleural mesotheliomaStrahlentherapie und Onkologie, 2017
- Malignant mesothelioma: Facts, Myths, and HypothesesJournal of Cellular Physiology, 2011